Comparative effects of rosuvastatin and atorvastatin on the risk of new-onset diabetes mellitus in patients with acute coronary syndrome receiving percutaneous coronary intervention:a retrospective cohort study

查看全文 作　　者：Cunhui [1,2]Jia;Rui [1,2]Tian;Mengzhi [1,2]Zong;Fangyun [1,2]Luan;Wenjun [1,2]Wang;Chuanbao [1,2]Li 机构地区：[1]Department of Emergency Medicine and Chest Pain Center,Qilu Hospital of Shandong University,Jinan,Shandong,China;[2]Key Laboratory of Emergency and Critical Care Medicine of Shandong Province,Qilu Hospital of Shandong University,Jinan,Shandong,China. 出　　处：《Emergency and Critical Care Medicine》索引2022年第2卷第4期,共5页 基　　金：the National Natural Science Foundation of China(82070388);the Taishan Pandeng Scholar Program of Shandong Province(tspd20181220);the National Natural Science Foundation of Shandong Province(ZR2020MH035). 摘　　要：Background:Statins are frequently prescribed to reduce cardiovascular morbidity and mortality by lowering low-density lipoprotein cholesterol levels.However,the use of statins leads to an increased incidence of new-onset type 2 diabetes mellitus(NODM).Our study aims to compare the effect of rosuvastatin versus atorvastatin on NODM in patients with acute coronary syndrome(ACS)who underwent percutaneous coronary intervention(PCI)within 18 months of follow-up.Methods:A retrospective cohort study was conducted on patients with ACS who underwent PCI and were treated with rosuvastatin or atorvastatin between June 2012 and June 2017.The survival functions between the 2 groups were estimated using the Kaplan-Meier method and compared using the log-rank test with NODM as the endpoint.Cox proportional hazards models were used to calculate hazard ratios(HRs)and 95%confidence intervals(CIs)for the risk factors of NODM.Results:In total,220 patients received rosuvastatin and 168 atorvastatin.The cumulative incidence of NODM in the rosuvastatin group was lower but did not reach statistical significance,compared with that in the atorvastatin group(7.27%vs.12.50%,respectively;log-rank P=0.08).Using Cox proportional hazards models,baseline fasting blood glucose level was associated with a statistically significant increase in the risk of NODM(HR:4.56;95%CI:2.83–7.36;P<0.01).Conclusion:Long-term use of moderate rosuvastatin had a similar incidence of NODM compared with atorvastatin in patients with ACS receiving PCI. 关 键 词：Acute coronary syndrome ATORVASTATIN New-onset diabetes mellitus Percutaneous coronary intervention ROSUVASTATIN